Anzeige
Mehr »
Donnerstag, 26.06.2025 - Börsentäglich über 12.000 News
Ein echter Gamechanger: Diese News kann den Grundstein für eine Neubewertung der Rock-Tech-Aktie legen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0EAT9 | ISIN: BE0003818359 | Ticker-Symbol: GXE
Tradegate
26.06.25 | 08:30
23,820 Euro
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
BEL Mid
AMX
1-Jahres-Chart
GALAPAGOS NV Chart 1 Jahr
5-Tage-Chart
GALAPAGOS NV 5-Tage-Chart
RealtimeGeldBriefZeit
23,92024,10022:51
23,96024,14022:00

Aktuelle News zur GALAPAGOS NV Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoGalapagos appoints Aaron Cox as CFO2
MoGalapagos NV: Galapagos Appoints Aaron Cox as Chief Financial Officer262Former Horizon CFO joins Galapagos with deep expertise in international corporate finance, M&A, business development and strategic leadership Mechelen, Belgium; June 23, 2025, 07:30 CET; regulated...
► Artikel lesen
FrGALAPAGOS NV - 6-K, Report of foreign issuer3
18.06.Galapagos NV: Galapagos Presented New Data at ICML 2025 From Cohort 3 of ATALANTA-1 in Relapsed/Refractory Indolent NHL Patients, Demonstrating High Complete Response and MRD Negativity Rates With CAR-T Candidate GLPG5101448Of the 34 patients enrolled in Cohort 3 of the ATALANTA-1 Phase 1/2 study, 32 received GLPG5101; 94% were infused with fresh CAR-T cells, and 93% were treated within seven days of manufacturing GLPG5101...
► Artikel lesen
12.06.Galapagos NV: Galapagos to Present New ATALANTA-1 CAR-T Data at EHA 2025, Highlighting Low Toxicity and Rapid, Decentralized Delivery of Fresh, Early-Memory-Enriched GLPG5101 in R/R NHL406Data reported from the ongoing ATALANTA-1 Phase 1/2 study in a heavily pretreated relapsed refractory non-Hodgkin's Lymphoma (R/R NHL) patient population demonstrate low rates of high-grade toxicities Of...
► Artikel lesen
28.05.GALAPAGOS NV - 6-K, Report of foreign issuer9
GALAPAGOS NV Aktie jetzt für 0€ handeln
27.05.Galapagos NV: Galapagos Creates New Subscription Right Plan593Mechelen, Belgium; May 27, 2025, 22:30 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its Board of Directors created 925,000 subscription rights under a new...
► Artikel lesen
14.05.Galapagos NV: Galapagos Announces Oral Presentations at EHA and ICML 2025 Featuring Promising New Data from ATALANTA-1 study of Investigational CAR-T Candidate GLPG5101555Mechelen, Belgium; May 14, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG), a global biotechnology company dedicated to transforming patient outcomes through life-changing science and innovation...
► Artikel lesen
13.05.Galapagos stock holds as CEO change, spinoff plans halted15
13.05.Galapagos Says 'No' to SpinCo and Instead Will Seek Deals for All Assets15
13.05.Galapagos backtracks on planned split2
13.05.Galapagos to reevaluate spinoff plans; names new CEO5
13.05.Galapagos gets cold feet over plans to split up company2
13.05.Galapagos drops plan to split after 'market developments'-
13.05.GALAPAGOS NV - 6-K, Report of foreign issuer2
13.05.Galapagos stoppt Unternehmensaufspaltung und prüft strategische Alternativen20
13.05.Galapagos halts corporate separation, explores strategic alternatives; shares rise3
13.05.Galapagos To Re-evaluate Separation Plan, To Explore Alternatives For Existing Businesses; Names CEO7
13.05.Galapagos NV: Galapagos Announces Strategic Update on Proposed Separation, Executive Leadership Transition and Board Changes481Galapagos to re-evaluate the implementation of the previously announced separation following regulatory and market developments Galapagos to explore all strategic alternatives for its existing businesses...
► Artikel lesen
24.04.Galapagos stock holds Market Perform rating at Raymond James14
Weiter >>
73 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
2,1,1